ArticleCancer medicine2020

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.

Yannan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.